Xian Liu, Qin Yu, Hai-Bo Mao, Jing-Bo Hu, Wei-Hua Liu
{"title":"Ultra-small curcumin-ruthenium coordination polymer nanodots prevent renal ischemia-reperfusion injury and the progression to chronic kidney disease.","authors":"Xian Liu, Qin Yu, Hai-Bo Mao, Jing-Bo Hu, Wei-Hua Liu","doi":"10.3389/fbioe.2024.1506909","DOIUrl":null,"url":null,"abstract":"<p><p>Renal ischemia-reperfusion (IR) induces tissue hypoxia, resulting in disrupted energy metabolism and heightened oxidative stress. These factors contribute to tubular cell damage, which is a leading cause of acute kidney injury (AKI) and can progress to chronic kidney disease (CKD). The excessive generation of reactive oxygen species (ROS) plays a crucial role in the pathogenesis of AKI. This study presents the synthesis of curcumin ultra-small coordination polymer (Ru/Cur) nanodots and their application in scavenging ROS in renal tissues. By adding ruthenium ions to a methanol solution containing the natural product curcumin, ultra-small Ru/Cur nanodots were successfully synthesized. To enhance the dispersibility of these nanoparticles in water, polyvinylpyrrolidone (PVP) was used as a growth aid, resulting in highly stable nanodots with sizes smaller than 10 nm. The results indicated that Ru/Cur nanodots effectively eliminated various ROS and demonstrated significant therapeutic effects and biocompatibility in IR-AKI mice, reducing markers of kidney function damage, alleviating renal oxidative stress, and decreasing inflammatory cell infiltration. Ru/Cur nanodots inhibited renal fibrosis by suppressing epithelial-mesenchymal transition and the secretion of transforming growth factor-β1 in the model of IR-AKI to chronic kidney disease (CKD). In summary, our findings confirm that Ru/Cur nanodots mitigate the pathological conditions associated with both AKI and its progression to CKD by reducing IR-induced tubular cell injury.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"12 ","pages":"1506909"},"PeriodicalIF":4.8000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772299/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2024.1506909","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Renal ischemia-reperfusion (IR) induces tissue hypoxia, resulting in disrupted energy metabolism and heightened oxidative stress. These factors contribute to tubular cell damage, which is a leading cause of acute kidney injury (AKI) and can progress to chronic kidney disease (CKD). The excessive generation of reactive oxygen species (ROS) plays a crucial role in the pathogenesis of AKI. This study presents the synthesis of curcumin ultra-small coordination polymer (Ru/Cur) nanodots and their application in scavenging ROS in renal tissues. By adding ruthenium ions to a methanol solution containing the natural product curcumin, ultra-small Ru/Cur nanodots were successfully synthesized. To enhance the dispersibility of these nanoparticles in water, polyvinylpyrrolidone (PVP) was used as a growth aid, resulting in highly stable nanodots with sizes smaller than 10 nm. The results indicated that Ru/Cur nanodots effectively eliminated various ROS and demonstrated significant therapeutic effects and biocompatibility in IR-AKI mice, reducing markers of kidney function damage, alleviating renal oxidative stress, and decreasing inflammatory cell infiltration. Ru/Cur nanodots inhibited renal fibrosis by suppressing epithelial-mesenchymal transition and the secretion of transforming growth factor-β1 in the model of IR-AKI to chronic kidney disease (CKD). In summary, our findings confirm that Ru/Cur nanodots mitigate the pathological conditions associated with both AKI and its progression to CKD by reducing IR-induced tubular cell injury.
期刊介绍：
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
